The Role of Adjuvant Hormonal Treatment after Surgery for Localized High-Risk Prostate Cancer: Results of a Matched Multiinstitutional Analysis

Table 2

Freedom from biochemical progression free-survival (BPFS), clinical progression-free (CPFS), cancer-specific (CSS), and overall survival (OS).

Projected survival	Group 1 ADT (𝑛=86)		Group 2 no ADT (𝑛=86)		𝑃 value
	5 years	10 years	5 years	10 years
BPFS	87.7%	76.3%	37.1%	30.6%	<0.001
CPFS	96.9%	94.3%	73.7%	67.0%	0.003
CSS	100%	100%	100%	91.0%	0.9
OS	94.4%	83.8%	97.1%	76.4%	0.6